OWC Pharmaceutical Research Corp (OWCP)

[Triple9]

Psoriasis phase 3 studies are due March 2017, and agreements have already been signed to begin production and sales in EU and US MMJ states in Q2.

I'm basing my valuation of OWCP on the expected revenue from the psoriasis cream in Q2, Q3, and Q4.

Psoriasis (Skin Disease)
• Pharma-grade ‘challenge tests’ successfully completed
05/2016
• Safety study at Sheba, Tel Hashomer under approved
IRB (Helsinki) protocol. To be completed 3/2017
• In-vitro psoriasis efficacy study of the topical crème to
be completed by 3/2017
• IP owned by OWCP
• EXPECTED MARKET READINESS : Q2/2017

http://www.owcpharma.com/wp-content/uploads/2017/01/OWC-PPT-1-2017-FINAL.pdf

Also note that OWCP is seeking approval to sale cremes for other skin conditions, "Acne, Basal cell carcinoma, Atopic dermatitis and more".

Based SOLELY on the sale of psoriasis creme, I see $3 per share price later this year. Add acne, dermatitis and eczema cremes and I see $5 per share.

Now add in that OWCP already has 3 consulting contracts (I'm hoping with major MMJ marketplaces like CA and MA). Now add in that OWCP is looking to license it's creme, sublingual tablet, and upcoming nasal spray delivery platforms to other MMJ companies and, I believe, we're looking at around $7 per share.

The Ace up OWCP's sleeve is:

Multiple Myeloma (Cancer)
• Designed to be an Orphan Disease study approved by the FDA
• In-vitro study completed 06/2015 – Cannabis kills the MM cancer cells
• Pre-clinic study on mice completed 12/2015 – calibration phase for dosage,
found most effective ratio of active cannabinoids THC/CBD
• In-vitro study for a combination of 4 approved drugs with cannabis completed
05/2016 – promising results
• Pre-clinic study for the most effective combination on mice with new cannabis
extracts. On-going testing.
• SUBJECT TO ACHIEVING SCIENTIFIC MILESTONES THE COMPANY WILL
SUBMITT AN APPLICATION WITH THE FDA FOR AN ORPHAN DISEASE
DESIGNATION

What is the value of a cure for cancer? Yes, this is longer term, but remember there is no current cure for Multiple Myeloma which, I believe, means fast track approval. People who are buying the stock today are, for capital gains avoidance consideration in some cases and to maximize profits in others, long term holders of the stock. The prices they are willing to pay today are weighed against their expectations of what the stock price will be in the future.